KeyBank National Association’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
– Sell
-4,058
Closed -$303K – 1194
2025
Q2
$303K Buy
+4,058
New +$269K ﹤0.01% 983
2018
Q2
– Sell
-18,675
Closed -$1.37M – 1055
2018
Q1
$1.37M Sell
18,675
-19,125
-51% -$1.31M 0.01% 437
2017
Q4
$2.19M Buy
37,800
+600
+2% +$31.6K 0.01% 342
2017
Q3
$1.67M Sell
37,200
-1,775
-5% -$73.7K 0.01% 403
2017
Q2
$1.54M Sell
38,975
-12,225
-24% -$502K 0.01% 426
2017
Q1
$2.08M Buy
51,200
+4,795
+10% +$187K 0.01% 358
2016
Q4
$1.86M Buy
46,405
+1,480
+3% +$55.8K 0.01% 385
2016
Q3
$1.63M Sell
44,925
-375
-0.8% -$12.9K 0.01% 414
2016
Q2
$1.31M Sell
45,300
-1,300
-3% -$39.3K 0.01% 449
2016
Q1
$1.63M Sell
46,600
-900
-2% -$29.1K 0.01% 393
2015
Q4
$1.53M Buy
47,500
+3,700
+8% +$120K 0.01% 424
2015
Q3
$1.42M Buy
43,800
+7,800
+22% +$294K 0.01% 451
2015
Q2
$1.49M Sell
36,000
-630
-2% -$26.6K 0.01% 480
2015
Q1
$1.65M Buy
36,630
+11,000
+43% +$460K 0.01% 465
2014
Q4
$959K Buy
+25,630
New +$939K 0.01% 647

Other funds holding HAE

KeyBank National Association's HAE Position: Q3 2025 in Review

KeyBank National Association sold out of Haemonetics (HAE) in Q3 2025, closing a stake of 4,058 shares — an estimated $303K sold.

KeyBank National Association first reported a position in HAE in Q4 2014 and held it in 15 quarters. The position peaked at $2.19M in Q4 2017. 301 funds tracked by Wall St. Rank hold HAE as of Q3 2025.

  • KeyBank National Association reported no remaining Haemonetics position as of Q3 2025 after selling out during the quarter.
  • KeyBank National Association sold 4,058 Haemonetics shares in Q3 2025, an estimated $303K.
  • KeyBank National Association first reported a position in Haemonetics in Q4 2014 and held it in 15 quarters.
  • KeyBank National Association's Haemonetics position peaked at $2.19M in Q4 2017.
  • 301 funds tracked by Wall St. Rank held Haemonetics as of Q3 2025.

Based on KeyBank National Association's 13F filing for Q3 2025, filed 4 Nov 2025.